Search results
Showing 646 to 660 of 1070 results for drug therapy
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.
Pegzilarginase for treating arginase-1 deficiency in people 2 years and over (HST35)
Evidence-based recommendations on pegzilarginase (Loargys) for treating arginase-1 deficiency in people 2 years and over.
Show all sections
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Extracorporeal shockwave therapy for refractory tennis elbow (HTG201)
Evidence-based recommendations on extracorporeal shockwave therapy for refractory tennis elbow. This involves using a machine to deliver sound waves to the painful area to stimulate healing.
View recommendations for HTG201Show all sections
Sections for HTG201
Extracorporeal shockwave therapy for refractory plantar fasciitis (HTG200)
Evidence-based recommendations on extracorporeal shockwave therapy for refractory plantar fasciitis. This involves using a machine to deliver sound waves to the painful area, with the aim to stimulate healing of the fascia.
View recommendations for HTG200Show all sections
Sections for HTG200
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
LiMAx system for assessing the functional capacity of the liver (MIB168)
NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .
MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (IPG671)
We have moved interventional procedures guidance 671 to become HealthTech guidance 541. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (HTG487)
Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder.
View recommendations for HTG487Show all sections
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)
This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.